Amphotericin B nephrotoxicity
- PMID:2182052
- DOI: 10.2165/00002018-199005020-00003
Amphotericin B nephrotoxicity
Abstract
The frequency of fungal infections is increasing. Amphotericin B remains the anti-fungal drug of choice for most systemic infections, but a limiting factor for its use is the development of nephrotoxicity. Amphotericin B-induced nephrotoxicity is manifested as azotaemia, renal tubular acidosis, impaired renal concentrating ability and electrolyte abnormalities like hypokalaemia and sodium and magnesium wasting. All these abnormalities occur to varying degrees in almost all patients receiving the drug. Upon withdrawal of therapy renal function gradually returns to baseline, although in some instances permanent damage is sustained, especially when the cumulative dose exceeds 5g. Salt depletion enhances the development of nephrotoxicity. The mechanism of nephrotoxicity involves direct cell membrane actions to increase permeability, as well as indirect effects secondary to activation of intrarenal mechanisms (tubuloglomerular feedback) and/or release of mediators (thromboxane A2). The latter effects are presumably responsible for the observed acute decreases in renal blood flow and filtration rate, responses that are inhibited by several physiological and pharmacological interventions. Changes in intracellular calcium levels may also contribute to the observed effects. In the clinical situation, and in long term models of nephrotoxicity in the rat, salt loading protects against deterioration in renal function; recommendations are made for the optimisation of amphotericin B therapy by salt loading. New preparations of the drug, such as liposomal amphotericin B, may also prove useful in minimising nephrotoxicity while maintaining antifungal activity, but further research is needed with both salt loading and liposomal amphotericin B to confirm or deny their protective effect on kidney function.
Similar articles
- Amphotericin B nephrotoxicity in children.Goldman RD, Koren G.Goldman RD, et al.J Pediatr Hematol Oncol. 2004 Jul;26(7):421-6. doi: 10.1097/00043426-200407000-00004.J Pediatr Hematol Oncol. 2004.PMID:15218415Review.
- Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity.Sabra R, Zeinoun N, Sharaf LH, Ghali R, Beshara G, Serhal H.Sabra R, et al.Pharmacol Toxicol. 2001 Apr;88(4):168-75. doi: 10.1034/j.1600-0773.2001.d01-99.x.Pharmacol Toxicol. 2001.PMID:11322173
- Mechanisms and management of amphotericin B-induced nephrotoxicity.Miano-Mason TM.Miano-Mason TM.Cancer Pract. 1997 May-Jun;5(3):176-81.Cancer Pract. 1997.PMID:9171554Review.
- Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline.Branch RA, Jackson EK, Jacqz E, Stein R, Ray WA, Ohnhaus EE, Meusers P, Heidemann H.Branch RA, et al.Klin Wochenschr. 1987 Jun 1;65(11):500-6. doi: 10.1007/BF01721035.Klin Wochenschr. 1987.PMID:3475498
- Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S.Karimzadeh I, et al.Expert Opin Drug Saf. 2012 Nov;11(6):969-83. doi: 10.1517/14740338.2012.721775. Epub 2012 Sep 5.Expert Opin Drug Saf. 2012.PMID:22950480Review.
Cited by
- Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ.Adler-Moore J, et al.Clin Infect Dis. 2019 May 2;68(Suppl 4):S244-S259. doi: 10.1093/cid/ciz064.Clin Infect Dis. 2019.PMID:31222254Free PMC article.Review.
- Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats.Tasset C, Preat V, Bernard A, Roland M.Tasset C, et al.Antimicrob Agents Chemother. 1992 Jul;36(7):1525-31. doi: 10.1128/AAC.36.7.1525.Antimicrob Agents Chemother. 1992.PMID:1510450Free PMC article.
- Outcome of post-COVID-19 fungal pyelonephritis: A single Indian tertiary center experience.Pathak NJ, Surwase PP, Karthik US, Patil AP, Konnur AM, Soni SM, Singh AG, Ganpule AP, Sabnis RB, Desai MR.Pathak NJ, et al.Indian J Urol. 2022 Apr-Jun;38(2):121-127. doi: 10.4103/iju.iju_31_22. Epub 2022 Apr 1.Indian J Urol. 2022.PMID:35400877Free PMC article.
- Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.Garcia-Effron G, Park S, Perlin DS.Garcia-Effron G, et al.Antimicrob Agents Chemother. 2009 Jan;53(1):112-22. doi: 10.1128/AAC.01162-08. Epub 2008 Oct 27.Antimicrob Agents Chemother. 2009.PMID:18955538Free PMC article.
- Reversible ototoxicity: a rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male.Das P, Kandel R, Sikka K, Dey A.Das P, et al.Clin Med Insights Case Rep. 2014 Jul 24;7:63-6. doi: 10.4137/CCRep.S15111. eCollection 2014.Clin Med Insights Case Rep. 2014.PMID:25093006Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical